Just in 👉data from SWOG Cancer Research Network 1216 trial in mHSPC#prostatecancer👉 PSA level at 3 and 7 months after starting ADT Rx are strongly prognostic of OS: It’s time to design de- or escalation trials based on response biomarkers. OPEN access👉 tinyurl.com/3azhpt4r OncoAlert UroToday.com

⭕️Early PSA responses predict survival 📈 in Metastatic Hormone-sensitive #ProstateCancer
⭕️Patients showing complete response at 3 & 7 months see remarkable OS benefits 💡
Kudos to Mamta Parikh, Neeraj Agarwal, MD, FASCO SWOG Cancer Research Network & the entire team for this insightful work! 👏
#Oncology …

WoW ! Amazing

To be read ! 👏👏

ENZA-P in The Lancet Oncology

Lu-177 PSMA-617 + enzalutamide vs. enza alone:

● ↑PFS: 13.0 vs 7.8, hazard radio 0.43
● PSA90 response 78% vs 37%
● PSA50 response 93% vs. 68%
● no additional side effects

Incredible work from Louise Emmett Ian Davis & ANZUP team…

Want a recap of Advanced Prostate Cancer updates from #EAU24 ? Catch this EAUTV where moderator Prof. A. Briganti and panelists Prof. K. Touijer, Dr. E. Briers, and Assoc. Prof. A. Morgans cover topics ranging from new trials to patient involvement. eaucongress.uroweb.org/eautv-advanced…

📒Commission on prostate cancer
The Lancet

✅Comprehensive report on epidemiology and future projected trends in cases, the diagnostic pathway, treatment, and management of advanced disease

👉thelancet.com/journals/lance…

The LancetOncol ESMO - Eur. Oncology ASCO American Cancer Society NHS England…

Do not yet abandon contrast in prostate MRI. You must check your image quality first with PI-QUAL (v2). Quality must be good, which is not the case in many MRI's.
Also, enhancement in an abnormality on T2W+DWI, especially in TZ, means a Gl4 component. Lack of enhancement is 3+3.

Is all PSA persistence created equal? Definition and diagnostic workup. Presentation by Derya Tilki, MD Martini-Klinik am UKE. #EAU24 written coverage by Rashid K. Sayyid University of Toronto > bit.ly/3vNtZ7f European Association of Urology (EAU)

Congrats Clémentine Le Magnen and the whole team from Basel ! See you in 2 weeks in #Lugano for the Translational #APCCC program ! #ProstateCancer

Thanks European Association of Urology (EAU) for a great #EAU24 meeting! Proud that our work on a #bladdercancer patient-derived #organoid biobank was awarded 3rd prize best oncology abstract 🥉! Congrats to the two first-authors Michele Garioni and Viviane Tschan ⭐️

Pelvic lymph node dissection in #ProstateCancer : Update of the limited vs. extended randomized clinical trial. Presented by Karim Touijer Memorial Sloan Kettering Cancer Center. #EAU24 written coverage by @rksayyid, MD, MSc University of Toronto > bit.ly/3VM5qCk European Association of Urology (EAU)

Satisfying data to keep extended LND by Karim Touijer #EAU24 European Association of Urology (EAU) ..

#EAU24 Simple, but super effective slide from Elena Castro for remembering the PARPi + ARPI combos approved for each patient type stratified by EMA vs FDA

UroToday.com

Summary review of #TPvsTR evidence #State_of_the_Art just out today in BJU International

Is LATP really better than TR?

3 RCTs now out...larger/definitive trials to follow TRANSLATE Trial/The Patient-Centered Outcomes Research Institute #EAU24

Thanks Matt Cooperberg & Michael Jewett for commissioning!

bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bj…

Congrats to the whole team and our rising star Peyrottes Arthur

#EAU24
The incredible PEACE-6 platform of European trials in mHSPC (Fizazi)

Important treatment escalation (Lu-PSMA, in poor PSA responders) and de-escalation (PSA responders 6-8 months) arms of the platform
UroToday.com

Incredible talk by ⁦Mauro GACCI⁩ at #EAU24 #Paris about prevention of benign prostatic disease - truth an lies about diet, sex, physical activity and more ⁦European Association of Urology (EAU)⁩ ⁦Christian Gratzke⁩

Merci à mes co-orateurs et Ipsen_FR pour l’organisation de ce Best Of EAU #EAU24 et dont le replay sera prochainement disponible Jonathan Olivier @ Priscilla Leon et Romain Boissier

New data from ERSCP on long term benefits of screening from 55 showing big reductions in metastases and risk of prostate cancer death #EAU24